CoChat
Cited by 176

The DOI matches its Crossref record.

Cold agglutinin disease revisited: a multinational, observational study of 232 patients

Open access
Berentsen, Sigbjørn, Barcellini, Wilma, D’Sa, Shirley, Randen, Ulla, Tvedt, Tor Henrik Anderson, Fattizzo, Bruno, Haukås, Einar, Kell, Megan, Brudevold, Robert, Dahm, Anders E. A., Dalgaard, Jakob, Frøen, Hege, Hallstensen, Randi Fykse, Jæger, Pernille H., Hjorth-Hansen, Henrik, Małecka, Agnieszka, Oksman, Markku, Rolke, Jürgen, Sekhar, Mallika, Sørbø, Jon Hjalmar, Tjønnfjord, Eirik, Tsykunova, Galina, Tjønnfjord, Geir E. · 2020 · Blood

Abstract

We retrospectively studied 232 patients with cold agglutinin disease (CAD) at 24 centers in 5 countries. In Norway and a northern region of Italy, the study was close to being population-based. For the first time, we demonstrate fourfold differences between cold and warmer climates regarding prevalence (20 vs 5 cases/million) and incidence (1.9 vs 0.48 cases/million per year). Mean baseline hemoglobin level was 9.3 g/dL, but 27% had hemoglobin <8 g/dL. Identification of typical features of CAD-associated lymphoproliferative disorder in the bone marrow was greatly increased by centralized biopsy assessment. CAD seems to be associated with a slightly increased risk of venous thrombosis. This work includes a follow-up study of therapies, focusing on the long-term outcomes of the rituximab plus bendamustine and rituximab plus fludarabine regimens. Rituximab plus bendamustine therapy resulted in responses in 35 (78%) of 45 patients; 24 (53%) achieved complete response. Interestingly, these rates were still higher than observed in the original (2017) prospective trial, and we also found a shift toward deeper responses with time. This is explained by the prolonged time to response seen in many patients, probably related to long-lived plasma cells. In patients responding to rituximab-bendamustine, median response duration was not reached after 88 months, and estimated 5-year sustained remission was 77%. The regimen appeared safe regarding late-occurring malignancies. Rituximab plus fludarabine therapy seems to carry a higher risk of long-term adverse effects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood.2020005674

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 176

Metadata

Authors
Berentsen, S., Barcellini, W., D’Sa, S., Randen, U., Tvedt, T. H. A., Fattizzo, B., Haukås, E., Kell, M., Brudevold, R., Dahm, A. E. A., Dalgaard, J., Frøen, H., Hallstensen, R. F., Jæger, P. H., Hjorth-Hansen, H., Małecka, A., Oksman, M., Rolke, J., Sekhar, M., Sørbø, J. H., Tjønnfjord, E., Tsykunova, G., & Tjønnfjord, G. E.
Venue
Blood
Published
2020-07-23
Volume
136
Issue
4
Pages
480-488
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W3022726062
Cited by
176
References
0
FWCI
12.29
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cold agglutinin disease revisited: a multinational, observational study of 232 patients. https://app.cochat.ai/papers/10.1182/blood.2020005674
The paper
Berentsen, S., Barcellini, W., D’Sa, S., Randen, U., Tvedt, T. H. A., Fattizzo, B., Haukås, E., Kell, M., Brudevold, R., Dahm, A. E. A., Dalgaard, J., Frøen, H., Hallstensen, R. F., Jæger, P. H., Hjorth-Hansen, H., Małecka, A., Oksman, M., Rolke, J., Sekhar, M., . . . Tjønnfjord, G. E. (2020). Cold agglutinin disease revisited: a multinational, observational study of 232 patients. Blood. https://doi.org/10.1182/blood.2020005674

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.